Given the unsatisfactory treatment response of particular subgroups of systemic ALCL, ALK− patients, relapsed/refractory systemic ALCL patients or relapsed pediatric ALCL, ALK+ patients to standard chemotherapy, there is a medical need for new effective treatment strategies49. This evidence concerns the gene ALK and anaplastic large cell lymphoma.